EUVIMEDEUVIMED entdecken
Kohortenstudie

Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study

Gursimran S Kochhar iD, Aakash Desai iD, Francis A Farraye, Raymond K Cross, Sandra El-Hachem, Parambir S Dulai iD, Miguel Regueiro

Alimentary Pharmacology & Therapeutics · 2023-08 · 58 (3) · 297-308

DOI: 10.1111/apt.17570 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 09.06.2023. Verfasst von Gursimran S Kochhar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited real‐world data on comparative effectiveness of different biologic or small molecule agents as second‐line therapies in patients with ulcerative colitis (UC) with prior exposure to a tumour necrosis factor inhibitor (TNFi).

Methods

We conducted a retrospective cohort study using TriNetX, a multi‐institutional database to assess the efficacy of tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis (UC) with prior exposure to a TNFi. Failure of medical therapy was defined as a composite outcome of intravenous steroids or colectomy within 2 years. One‐to‐one propensity score matching was performed for demographics, disease extent, mean haemoglobin, C‐reactive protein, albumin and calprotectin, prior IBD medications and steroid use between cohorts.

Results

Among 2141 patients with UC and prior exposure to TNFi, 348 (16.2%), 716 (33.4%) and 1077 (50.3%) were switched to tofacitinib, ustekinumab and vedolizumab, respectively. After propensity‐score matching, there was no difference in the composite outcome (aOR: 0.77, 95% CI: 0.55–1.07) but higher risk of colectomy (aOR: 2.69, 95% CI: 1.31–5.50) in the tofacitinib cohort than the vedolizumab cohort. There was no difference in the risk of composite outcome (aOR: 1.29, 95% CI: 0.89–1.86) but higher risk of colectomy (aOR: 2.63, 95% CI: 1.24–5.58) in the tofacitinib cohort than the ustekinumab cohort. The vedolizumab cohort had a higher risk of composite outcome (aOR: 1.67, 95% CI: 1.29–2.16) than the ustekinumab cohort.

Conclusion

Ustekinumab might be the preferred second‐line therapy over tofacitinib and vedolizumab in patients with UC that were previously exposed to a TNFi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsHumansUstekinumabTumor Necrosis Factor InhibitorsCohort StudiesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

tofacitinibtumour necrosis factor inhibitorulcerative colitisustekinumabvedolizumab

Substanzen

UstekinumabTumor Necrosis Factor InhibitorsBiological Products

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Division of Gastroenterology & Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Division of Gastroenterology, Hepatology & Nutrition, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Gastroenterology & Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Division of Gastroenterology, Hepatology & Nutrition, Northwestern University, Chicago, Illinois, USA.
  • Division of Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Gursimran S Kochhar, Aakash Desai, Parambir S Dulai

Zitieren

APA

Kochhar, G. S., Desai, A., Farraye, F. A., Cross, R. K., El-Hachem, S., Dulai, P. S., & Regueiro, M. (2023). Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study. Alimentary Pharmacology & Therapeutics, 58(3), 297-308. https://doi.org/10.1111/apt.17570

Vancouver

Kochhar GS, Desai A, Farraye FA, Cross RK, El-Hachem S, Dulai PS, et al. Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study. Alimentary Pharmacology & Therapeutics. 2023;58(3):297-308. doi:10.1111/apt.17570

BibTeX
@article{Kochhar2023,
  author = {Kochhar, Gursimran S and Desai, Aakash and Farraye, Francis A and Cross, Raymond K and El-Hachem, Sandra and Dulai, Parambir S and Regueiro, Miguel},
  title = {Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {58},
  number = {3},
  pages = {297--308},
  doi = {10.1111/apt.17570}
}
Kostenlos starten →